|
Chỉ định và Liều dùng
Oral
Peripheral vascular disease Adult: For the treatment of cases such as intermittent claudication, night cramps, rest pain, Raynaud's syndrome, incipient gangrene, trophic ulcers, diabetic arteriopathy and acrocyanosis: 100-200 mg tid. Alternative recommended dose for Raynaud's syndrome: As tab: 200 mg bid. Dosing recommendations may vary among countries and individual products (refer to specific product guidelines).
|
|
Các sản phẩm có chứa hoạt chất Naftidrofuryl tại Việt Nam?
|
|
Cách dùng
Should be taken with food.
|
|
Chống chỉ định
History of hyperoxaluria or recurrent Ca-containing renal stones.
|
|
Thận trọng
Renal and hepatic impairment.
|
|
Tác dụng không mong muốn
Significant: Local oesophagitis (when taken without liquid before lying down); rarely, liver damage; very rarely, Ca oxalate kidney stones.
Gastrointestinal disorders: Nausea, vomiting, epigastric pain, diarrhoea. Skin and subcutaneous tissue disorders: Rash. |
|
Thông tin tư vấn bệnh nhân
Administer with an adequate amount of fluid, particularly if taken before lying down. Ensure sufficient fluid intake during treatment to reduce the risk of kidney stones.
|
|
Quá liều
Symptoms: Convulsions, depression of cardiac conductions. Management: Perform gastric lavage and induce emesis. May administer activated charcoal if needed. Monitor CV function and respiration. For severe cases, may consider electrical pacemaking or administration of isoprenaline. May give diazepam for convulsions.
|
|
Tác dụng
Description:
Mechanism of Action: Naftidrofuryl, a 5-HT2 receptor antagonist, produces vasodilation on both peripheral and cerebral circulation. It also activates intracellular aerobic metabolism which may provide cell protection against metabolic effects of ischaemia by increasing ATP levels and reducing lactic acid levels. Furthermore, it is a potent spasmolytic agent. Synonym: nafronyl. Pharmacokinetics: Absorption: Well absorbed. Bioavailability: 17-32%. Time to peak plasma concentration: 30-45 minutes (cap); 2-3 hours (tab). Distribution: Plasma protein binding: 92%, mainly albumin. Metabolism: Primarily metabolised via hydrolysis into inactive metabolites. Excretion: Via urine (80% as metabolites). Elimination half-life: 0.8-1.6 hours (cap); 3-4 hours (tab). |
|
Đặc tính
 Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 4417, Naftidrofuryl. https://pubchem.ncbi.nlm.nih.gov/compound/Naftidrofuryl. Accessed June 25, 2021. |
|
Bảo quản
Store below 25°C. Protect from moisture and light.
|
|
Phân loại MIMS
|
|
Phân loại ATC
C04AX21 - naftidrofuryl ; Belongs to the class of other peripheral vasodilators.
|
|
Tài liệu tham khảo
Anon. Naftidrofuryl (Nafronyl). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/06/2021. Buckingham R (ed). Naftidrofuryl Oxalate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/06/2021. Joint Formulary Committee. Naftidrofuryl Oxalate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/06/2021. Naftidrofuryl Capsules BP 100 mg (Accord-UK Ltd). MHRA. https://products.mhra.gov.uk. Accessed 04/06/2021.
|
Đăng ký miễn phí để được tiếp tục đọc
Tiếp tục với Google
Đăng ký với email
Đã là thành viên?
Đăng nhập
Đăng xuất
